Everything below concerns lyophilized powder. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
The Pearl Index, also called the Pearl rate, is the most common technique used in clinical trials for reporting the effectiveness of a birth control method. It is a very approximate measure of the number of unintended pregnancies in 100 woman-years of exposure that is simple to calculate, but has a number of methodological deficiencies. The index was introduced by Raymond Pearl in 1934. It has remained popular for over eighty years, in large part because of the simplicity of the calculation. Several kinds of information are needed to calculate a Pearl Index for a particular study: the total number of months or cycles of exposure by women in the study the number of pregnancies the reason for leaving the study (pregnancy or other reason) There are two calculation methods for determining the Pearl Index:
In February 2014, Bhabha Atomic Research Centre (BARC), in Mumbai, India, presented their latest design for a "next-generation nuclear reactor" that burns thorium as its fuel core, calling it the Advanced Heavy Water Reactor (AHWR). In 2009, the chairman of the Indian Atomic Energy Commission said that India has a "long-term objective goal of becoming energy-independent based on its vast thorium resources." On 16 June 2023 China's National Nuclear Safety Administration issued a licence to the Shanghai Institute of Applied Physics (SINAP) of the Chinese Academy of Sciences to begin operating the TMSR-LF1, 2 MWt liquid fuel thorium-based molten salt experimental reactor which was completed in August 2021. China is believed to have one of the largest thorium reserves in the world. The exact size of those reserves has not been publicly disclosed, but it is estimated to be enough to meet the country's total energy needs for more than 20,000 years.
=== Brand names === As of 2018, the combination is marketed under several brand names, including Efficib, Janmet, Januet, Janumet, Jznumet, Ristaben Met, Ristfor, Siglimet, Sitamet, Sitar-M, Sliptin-M, Treviamet, Velmetia, Istamet, Emsita, Sitaglyn, Sitazit-M, and Zaxoran.
=== 2021–2023 === In 2022, MSNBC described Trump as "notoriously secretive about sharing his health records with the public" and "deliberately misleading and even dishonest about his health". In an incident in October 2023, Trump referred to Hungarian prime minister Viktor Orbán as "the leader of Turkey", and said that Orbán shares a border with Russia, which neither Turkey nor Hungary does.
Sources: en.wikipedia.org
Refugees typically rely on limited sources of vitamin B3 provided to them, often peanuts (which, in Africa, may be supplied in place of local groundnut staples, such as the Bambara or Hausa groundnut); the instability in the nutritional content and distribution of food aid can be the cause of pellagra in displaced populations. In the 2000s, outbreaks occurred in countries such as Angola, Zimbabwe, and Nepal. In Angola specifically, recent reports show a similar incidence of pellagra since 2002, with clinical pellagra in 0.3% of women and 0.2% of children, and niacin deficiency in 29.4% of women and 6% of children related to high untreated corn consumption. In other countries such as the Netherlands and Denmark, even with sufficient intake of niacin, cases have been reported. In this case, deficiency might happen not just because of poverty or malnutrition, but secondary to alcoholism, drug interaction (psychotropic, cytostatic, tuberculostatic, or analgesics), HIV, vitamin B2 and B6 deficiency, or malabsorption syndromes such as Hartnup disease and carcinoid tumors.
=== Energy === Schleswig-Holstein is a leader in the country's growing renewable energy industry. In 2014, Schleswig-Holstein became the first German state to cover 100% of its electric power demand with renewable energy sources (chiefly wind 70%, solar 3.8%, and biomass 8.3%). By 2023, according to Schleswig-Holstein Netz, renewable energy sources were providing 204% of Schleswig-Holstein's electricity demand (the 104% surplus are exports). The largest German oil field Mittelplate is located in the North Sea off the Dithmarsch coast and connected with a refinery in Hemmingstedt and chemical plants in Brunsbüttel via pipeline. It produces ca. 1.4 million tonnes of oil annually.
Generalmajor Walter Hörnlein - 1 April 1942 – 3 April 1943 Generalleutnant Hermann Balck - 3 April - 30 June 1943 Generalleutnant Walter Hörnlein - 30 June 1943 - 1 February 1944 Generalleutnant Hasso von Manteuffel - 1 February 1944 – August 1944 Generalmajor Karl Lorenz - 1 September 1944 - 7 May 1945
Sources: en.wikipedia.org
From about 1989 to 2018, Ontario has reported a deficit almost every year; the province's net debt increased to approximately $311.6 billion (by October 2018); and Ontario's net debt‐to‐GDP ratio grew from 13.4% to about 40.5% in 2018–19. According to an April 11, 2018 Royal Bank of Canada (RBC) report, which was based on figures provided by the Ford government, the revised estimate of Ontario's deficit was $11.7 billion in 2018–2019 and it was projected to decrease by $1.4 billion in 2019–2020 mainly because of "the removal of the $1 billion contingency reserve." At that time, it was projected that the deficit would be "completely eliminated in 2023–2024 with a small surplus of $0.3 billion." By October 2019, the Financial Accountability Officer, Weltman, said that the FAO had been in error when they—and the Ford government—had projected a $11.7-billion deficit that was reported in the spring 2019 budget. By June 2018, Ontario had "Canada's second-highest public debt per person and a growing budget deficit", according to The Economist. In October 2018, the Ontario Finance Department reported that Ontario's public debt per person, at $23,014, had surpassed that of Quebec at $21,606 in the fiscal year 2017–2018. Newfoundland and Labrador's public debt per capita, at $27,761, was the highest in Canada. By 2019, the Ontario Chamber of Commerce reported that Ontario's debt was over $348 billion—representing about 41% of provincial GDP of almost $850 billion. Ontario's GDP is much larger than any of the other provinces and is almost half of Canada's GDP.
== Treatment == If nipple pain is not resolved effectively after general management, appropriate treatment can be directed at underlying causes. Nevertheless, except the general management mentioned before, all common therapeutic practices in treating nipple pain during breastfeeding are not proven to be effective yet.
=== Degradative enzymes === Like any second messenger system, the signal must be terminated and there must be routes for NAADP removal but again, little is known with any degree of certainty. A 2'-3'-phosphatase stimulated by Ca2+ has been proposed in brain and, possibly in pancreatic acinar cells, that catabolises NAADP to inactive NAAD. CD38 has also been found to breakdown NAADP (to ADPRP — see inset). NAADP may also be reduced to NAADPH.
Especially the Danes developed a thriving livestock breeding industry, driving large herds along the Hærvejen to sell on the continent. This trade gave the route its alternative names, such as "Studevejen" (Cattle Way) in Danish and "Ochsenweg" (Oxen Way) in German. Therefore control of the Danevirke, through which the Hærvejen ran, was of immense financial significance. Whoever controlled the gates of Danevirke also controlled the trade along the Hærvejen, giving them access to substantial wealth.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.